Your Voice May Reveal Alzheimer’s Years Before Diagnosis, Landmark Review Finds

The way you speak may carry hidden fingerprints of cognitive decline, and a sweeping new analysis of a decade of research suggests those fingerprints could soon be read by machines. A scoping review published on 24 September 2026 in BioMedical Engineering OnLine maps ten years of progress in using speech and voice characteristics as biomarkers for Alzheimer’s disease and related dementias, and its verdict is striking: the field has matured from niche acoustic measurements into an era of powerful deep-learning models that can distinguish affected from unaffected speakers with reported accuracies of 70 to 95 percent, at least under controlled experimental conditions. The review, led by Shiva Akbari of the Institute of Biomedical Engineering at the University of Toronto and the KITE Research Institute at University Health Network, together with Grace Isaac of the University of California, Berkeley, and Azadeh Yadollahi of the University of Toronto and KITE, follows PRISMA-ScR reporting guidelines and synthesizes evidence that could shape how cognitive impairment is screened and monitored in the years ahead.

The stakes of the search are enormous. Alzheimer’s disease and related dementias are among the leading causes of disability and dependency in aging populations, and current diagnostic pathways rely heavily on clinical assessment, cognitive testing, and, in many settings, costly imaging or invasive procedures. Speech, by contrast, is cheap, abundant, and non-invasive. A short recording of someone describing a picture or naming words can be captured on a smartphone in minutes, which is precisely why researchers have spent the past decade asking whether subtle changes in pausing, pitch, articulation, and word choice might flag neurodegeneration long before memory complaints become obvious. The idea is not that speech replaces clinicians, but that it could provide an accessible early-warning signal, particularly valuable for repeated monitoring over time.

To build a rigorous map of this fast-moving field, the authors searched four major databases, PubMed, Scopus, IEEE Xplore, and the ACM Digital Library, in September 2025. They included studies that applied artificial intelligence, machine learning, or digital signal processing to speech data from individuals with Alzheimer’s disease, mild cognitive impairment, or related dementias. Out of the literature surveyed, 39 studies met the inclusion criteria. That number may sound modest for a decade of work, but the review’s value lies less in counting studies than in dissecting how the underlying technology has evolved, from handcrafted acoustic features engineered by human experts to self-supervised speech models that learn representations directly from raw audio.

That technological arc is the review’s central story. In the earlier phase of the field, researchers typically extracted handcrafted acoustic features, measurable quantities such as fundamental frequency, jitter, shimmer, pause durations, and spectral characteristics, and fed them into classical machine-learning classifiers. The review documents the continued use of support vector machines and random forests, workhorse algorithms that remain interpretable and effective on small datasets. More recently, however, the field has shifted decisively toward deep learning. Convolutional neural networks and transformer-based architectures now appear throughout the literature, and after 2020 the review found a clear increase in the use of self-supervised speech representation models such as wav2vec 2.0 and HuBERT. These models, pre-trained on vast amounts of unlabeled audio, produce rich embeddings of speech that can capture patterns no hand-engineered feature would think to measure.

The performance numbers reported across the 39 studies are eye-catching. Several studies reported classification accuracies between 70 and 95 percent when distinguishing people with Alzheimer’s disease, mild cognitive impairment, or related dementias from healthy controls. Studies using deep learning and self-supervised methods often reported higher performance than those relying on classical pipelines. Yet the review is careful to temper the excitement: reported performance varied substantially across datasets, speech tasks, feature extraction approaches, and validation protocols, which makes direct comparison between studies genuinely difficult. A 95 percent accuracy achieved on a small, homogeneous dataset with generous validation practices does not mean the same thing as a 75 percent accuracy achieved with rigorous leave-one-subject-out testing on a diverse cohort.

This caveat points to the review’s most sobering findings. The authors identify substantial challenges that stand between promising laboratory results and clinical reality. External validation is limited, meaning many models have been evaluated only on the same kinds of data they were trained on, leaving their performance on new populations, recording devices, and languages uncertain. Dataset heterogeneity is pervasive: studies differ in the speech tasks used, from picture description to fluency tests, in the diagnostic criteria applied, and in the demographic composition of participants. Reporting practices are inconsistent, so readers often cannot tell exactly how a model was validated. And as models grow more complex, their interpretability shrinks, making it harder for clinicians to understand why a system flagged a particular recording as concerning.

Interpretability is not a cosmetic concern; it is central to clinical trust. The review notes that techniques such as SHAP and LIME, which are designed to explain the predictions of machine-learning models, appear in the literature as researchers grapple with the black-box problem. A screening tool that tells a physician a patient is at risk without explaining which vocal or linguistic features drove the decision is unlikely to be adopted, and could also mask spurious correlations, for example patterns tied to recording conditions rather than to the brain. The review’s authors argue that reproducible, multimodal, and clinically interpretable speech biomarkers are what the field must now build, rather than chasing ever-higher accuracy numbers on benchmark datasets.

What makes the review timely is the convergence of several trends. Populations are aging rapidly, health systems are strained, and digital health tools have normalized the idea of collecting physiological data through everyday devices. Speech sits at a unique intersection of the neurological, cognitive, and motor systems, so its degradation in dementia plausibly reflects multiple disease processes at once. Self-supervised models trained on millions of hours of audio have made it feasible to extract subtle, generalizable representations from short recordings, something that was impractical when researchers had to define every feature by hand. The review documents that this shift accelerated after 2020, and it maps the methodological landscape in enough detail to serve as a reference point for the next wave of studies.

For readers wondering what a speech-based dementia screen might actually look like in practice, the review’s framing of three use cases is instructive: screening, monitoring, and staging. Screening would mean flagging individuals in the community or primary care who warrant fuller cognitive assessment. Monitoring would mean tracking the same person’s speech over months or years to detect change, an application where the non-invasive nature of speech is a decisive advantage. Staging would mean estimating disease severity, potentially aligning speech-derived measures with established cognitive scales such as the Mini-Mental State Examination or the cognitive subscale of the Alzheimer’s Disease Assessment Scale, both of which appear in the reviewed literature as reference standards. Each application imposes different demands on accuracy, reliability, and fairness, and the review makes clear that the evidence base is strongest for classification tasks and thinnest for longitudinal monitoring.

The path forward, as the authors frame it, requires addressing the gaps they catalog: larger and more diverse datasets, consistent external validation, standardized reporting, and models whose decisions clinicians can interrogate. The review itself received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors, and it is published open access under a Creative Commons license, making its full mapping of the field freely available to researchers worldwide. Whether voice becomes a routine vital sign for the aging brain will depend on whether the field can convert a decade of promising, fragmented results into reproducible, clinically interpretable tools. This review draws that map, and it marks exactly where the terrain is still uncharted.

Subject of Research: Speech and voice-based AI biomarkers for screening and monitoring Alzheimer's disease and related dementias

Article Title: A decade of advances in speech and voice-based biomarkers for Alzheimer’s disease and dementia: a scoping review

Article References: Akbari, S., Isaac, G., & Yadollahi, A. (2026). A decade of advances in speech and voice-based biomarkers for Alzheimer’s disease and dementia: a scoping review. BioMedical Engineering OnLine. https://doi.org/10.1186/s12938-026-01631-5

Image Credits: AI Generated

DOI: 10.1186/s12938-026-01631-5

Keywords: Alzheimer's disease, dementia, speech biomarkers, machine learning, deep learning, self-supervised learning, wav2vec 2.0, HuBERT, digital signal processing, mild cognitive impairment, scoping review, clinical interpretability